US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ODDITY Tech Ltd.

72.28

-1.7150-2.32%

Post-market: 72.280.00000.00%17:54 EDT

Volume:858.72K

Turnover:62.11M

Market Cap:4.03B

PE:41.61

High:73.86

Open:72.50

Low:71.08

Close:73.99

Loading ...

Overview Company News Filings

Oddity Tech (NasdaqGM:ODD) Surges 13% Last Quarter Following Strong Earnings with Sales Hitting US$124M

Simply Wall St.

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

3 Stocks That May Be Trading Up To 36.1% Below Their Intrinsic Value Estimates

Simply Wall St.

CVKD: Preparing for Phase 3 Trial of Tecarfarin…

Zacks Small Cap Research

Press Release: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation

MT Newswires Live

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

ACCESS Newswire

Press Release: Jacobio Pharma Announces 2024 Annual Results

3 High Growth Companies With Strong Insider Ownership

Simply Wall St.

BioArctic receives Orphan Drug Designation for exidavnemab the US

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Is Oddity Tech Ltd.'s (NASDAQ:ODD) Latest Stock Performance A Reflection Of Its Financial Health?

Simply Wall St.

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Oddity Tech (ODD) Just Overtook the 20-Day Moving Average

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

Oddity Tech Ltd. (ODD): A Bull Case Theory

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ODD/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":72.275,"timestamp":1749844800000,"preClose":73.99,"halted":0,"volume":858719,"hourTrading":{"tag":"盘后","latestPrice":72.275,"preClose":72.275,"latestTime":"17:54 EDT","volume":34660,"amount":2505027.195,"timestamp":1749851648341},"delay":0,"floatShares":38704922,"shares":55828291,"eps":1.736982,"marketStatus":"Market Closed","change":-1.715,"latestTime":"06-13 16:00:00 EDT","open":72.5,"high":73.86,"low":71.0801,"amount":62108509.002670005,"amplitude":0.037571,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.736982,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":73.99,"preHourTrading":{"tag":"盘前","latestPrice":72,"preClose":73.99,"latestTime":"09:29 EDT","volume":2335,"amount":167094.86495,"timestamp":1749821395076},"postHourTrading":{"tag":"盘后","latestPrice":72.275,"preClose":72.275,"latestTime":"17:54 EDT","volume":34660,"amount":2505027.195,"timestamp":1749851648341},"volumeRatio":0.43898084332611054,"impliedVol":0.6025,"impliedVolPercentile":0.44},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":38704922,"roa":"14.35%","roe":"32.25%","lyrEps":1.769608,"volumeRatio":0.43898084332611054,"shares":55828291,"dividePrice":0,"high":73.86,"amplitude":0.037571,"preClose":73.99,"low":71.0801,"week52Low":32.71,"pbRate":"12.24","psRate":"5.74","week52High":79.1804,"institutionHeld":0,"latestPrice":72.275,"eps":1.736982,"divideRate":0,"volume":858719,"delay":0,"ttmEps":1.736982,"open":72.5,"prevYearClose":42.02,"prevWeekClose":77.35,"prevMonthClose":74.43,"prevQuarterClose":43.26,"fiveDayClose":77.35,"twentyDayClose":63.25,"sixtyDayClose":43.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524921208","title":"Oddity Tech (NasdaqGM:ODD) Surges 13% Last Quarter Following Strong Earnings with Sales Hitting US$124M","url":"https://stock-news.laohu8.com/highlight/detail?id=2524921208","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524921208?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:54","pubTimestamp":1743702899,"startTime":"0","endTime":"0","summary":"Oddity Tech (NasdaqGM:ODD) recently reported a last-quarter price move of 13%, which coincides with a series of impactful company events. Notably, the company released strong fourth-quarter results, with sales increasing to $124 million from $97 million year-over-year, alongside an active share buyback program that saw 2.35 million shares repurchased, reflecting positive investor support. Additionally, Oddity Tech issued optimistic guidance for 2025, with expectations for increased revenue...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-nasdaqgmodd-surges-13-last-quarter-following-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2524025521","title":"Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524025521","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524025521?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., April 03, 2025----Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company’s commitment to advancing innovation and clinical development in anticoagulation therapy.Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and key opinion leaders in anticoagulation therapy.Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us on LinkedIn.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cadrenal-therapeutics-participates-key-medical-120000485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4183","BK4139","BK4007","CVKD","ODD"],"gpt_icon":0},{"id":"2524253142","title":"3 Stocks That May Be Trading Up To 36.1% Below Their Intrinsic Value Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2524253142","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524253142?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:07","pubTimestamp":1743678470,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a turbulent phase marked by recent tariff announcements and volatile trading sessions, investors are keenly assessing opportunities that may arise from these fluctuations. In such an environment, identifying stocks potentially undervalued relative to their intrinsic value becomes crucial, as these could offer significant upside potential once market conditions stabilize.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: Intuit Inc. offers financial management, compliance, and marketing products and services in the United States with a market cap of approximately $171.59 billion.Operations: The company's revenue segments include Pro-Tax at $594 million, Consumer at $4.45 billion, Credit Karma at $1.96 billion, and Global Business Solutions at $10.16 billion.Intuit is trading at US$620.91, below its estimated fair value of US$812.22, indicating potential undervaluation based on cash flows. Its earnings are projected to grow fa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-may-trading-36-110750631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1046422090.SGD","INTU","BHLB","ASB","IE00B7SZLL34.SGD","BK4213","LU1169589451.USD","EQT","BK4211","LU0274383008.USD","LU1169590202.USD","BK4588","ODD","BK4585","BK4114","BK4505","PFS","BK4220","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B19Z3581.USD","BK4195","CINT","BK4134","LU0006061336.USD"],"gpt_icon":1},{"id":"2524974387","title":"CVKD: Preparing for Phase 3 Trial of Tecarfarin…","url":"https://stock-news.laohu8.com/highlight/detail?id=2524974387","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524974387?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:24","pubTimestamp":1743431040,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics, Inc.  is a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant intended to prevent heart attacks, stroke, and death due to blood clots in patients suffering from rare cardiovascular conditions requiring chronic anticoagulation. These conditions include patients with left ventricular assist devices , patients with end-stage kidney disease  and atrial fibrillation , and patients with mechanical heart valves with difficult-to-control time in therapeutic range .The company is currently preparing for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices  trial. Recently, Cardrenal announced a collaboration agreement with Abbott in which Abbott will assist Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise. Abbott is the maker of the HeartMate 3 LVAD, which is the only LVAD currently approved in the U.S.As of December 31, 2024, Cadrenal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvkd-preparing-phase-3-trial-142400100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4592","LU0266013472.USD","BK4566","LU1721429741.USD","BK4139","LU1989763690.USD","BK4183","LU2237957811.SGD","LU0868494617.USD","BK4588","ODD","LU1914381329.SGD","LU1061106388.HKD","IE00BJJMRZ35.SGD","SG9999002224.SGD","SG9999004303.SGD","IE00B2B36J28.USD","BK4007","LU2112291526.USD","LU0234572021.USD","IE0002141913.USD","LU1023059063.AUD","LU2089984988.USD","LU2468319806.SGD","CDMO","BK4581","BK4585","BK4504","SG9999002232.USD","IE00BFTCPJ56.SGD","ABT","BK4533","LU1057294990.SGD","IE00BJT1NW94.SGD","LU1691799644.USD","BK4568","BK4082","CVKD","IE00B4R5TH58.HKD","LU1989763427.SGD","LU2133065610.SGD","LU1721429402.USD","IE0009355771.USD","LU0122379950.USD","LU2237957902.USD","LU0170899867.USD","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2522539975","title":"Press Release: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539975","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539975?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Company to Host Conference Call Today, March 27, at 4:30pm ET. BOCA RATON, Fla., March 27, 2025  -- INmune Bio Inc.  , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update.-- Announced completion of enrollment for its Phase 2 trial on Friday, 27. September, 2024. This global, blinded, randomized Phase 2 trial (the. \"AD02 trial\") is focused on patients with Early Alzheimer's Disease . and biomarkers of elevated neuroinflammation. Final enrollment of 208. patients exceeded the trial's target enrollment of 201 patients.-- Completed two separate interim analyses of blinded data from its AD02. trial. The analyses demonstrated exceptional performance of the novel. cognitive measure EMACC, as well as highly significant correlation. and CDR-SB, the key cognitive endpoints in the AD02 trial.--","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4183","03160","ODD","BK4604","BK4555","INMB","BK4139","R","BK4108","BK4099","CRS","TM","BK4585","BK4022","IE0031619046.USD","EB","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4232","BK4588","LU2065731478.USD","BK4077","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2522532250","title":"Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532250","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532250?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 27, 2025  -- Crinetics Pharmaceuticals, Inc.  today announced that the European Medicines Agency  has validated the Marketing Authorization Application  for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth hormone. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use . Additionally, the EMA on February 27, 2025 granted paltusotine Orphan Drug Designation  for the treatment of acromegaly.The EMA grants orphan designation to medicines intended for the treatment, prevention, or diagnosis of life-threatening or chronically debilitating diseases affecting no more than 5 in 10,000 people in the European Union, among other criteria. The medicine must also provide significant benefit to those affected by th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crinetics-pharmaceuticals-announces-european-medicines-200500366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAA","BK4215","BK4183","BK4139","CHMP","BK4551","BK4588","GH","BK4196","MDCO","BK4087","BK4585","BK4535","CRNX","ODD"],"gpt_icon":0},{"id":"2522134338","title":"Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522134338","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522134338?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:44","pubTimestamp":1743061459,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology  said its novel CD228-directed antibody-drug conjugate , BA1302, received Orphan Drug Designation  from the Food and Drug Administration  for the treatment of squamous non-small cell lung cancer  and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.The biopharmaceutical company's shares were up 2% in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODD","BK4183","BK7095","ADC","ADC.AU","BK4080","BK1161","06955","BK4231"],"gpt_icon":0},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI","ASH","R","BK4161","LU2355687059.USD","OS","BK4588","LU2463526074.USD","SLS","BK4183","LU1571399168.USD","BK4107","ALL","LU0985320562.USD","BK4022","BK4533","BK4232","CR","BK4213","BK4181","ORR","INN","BK4585","BK4097","BK4139","PR","ODD","BK4109","BK4218","LU1699723380.USD"],"gpt_icon":0},{"id":"2520107816","title":"BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2520107816","media":"ACCESS Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520107816?lang=en_us&edition=fundamental","pubTime":"2025-03-20 15:20","pubTimestamp":1742455200,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  for BI-1808, a first-in-class anti-TNFR2 antibody for the treatment of T-cell Lymphoma .\"We are excited to receive the FDA's Orphan Drug Designation for the treatment of TCL. This designation along with the recently announced positive Phase 2a data in CTCL reinforces our continued progress and commitment to developing BI-1808 as a potential novel class of immunomodulatory agents for TCL\", said Martin Welschof, Chief Executive Officer of BioInvent. \"We look forward to working closely with the regulatory agencies to accelerate the development of BI-1808 and bring this innovative treatment to patients who are in great need of new treatment options.\". About the Phase 1/2a studyDur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-fda-orphan-drug-072000957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SD","BOVNF","CR","BK4139","PR","ODD","BK4183","BK4213","BK4161"],"gpt_icon":0},{"id":"2520513307","title":"Press Release: Jacobio Pharma Announces 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520513307","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520513307?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:42","pubTimestamp":1742391720,"startTime":"0","endTime":"0","summary":"BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma  released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to RMB1.45 billion. Jacobio also announced recent business progress and expected milestones.\"2024 is a transforatmive year for Jacobio. We have submitted a New Drug Application  for the KRAS G12C inhibitor glecirasib and have licensed out the China rights of glecirasib and the SHP2 inhibitor sitneprotafib to our partner. This marks  Jacobio's  successful transformation  from the early R&D stage to an innovation-driven value realization stage,\" said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. \"Looking ahead to 2025, glecirasib is expected to receive the official approval for marking, which will continuously generate cash flow to invest in Jacobio' ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","ODD","01167","BK4183","BK1574","BK1161"],"gpt_icon":0},{"id":"2520704989","title":"3 High Growth Companies With Strong Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2520704989","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520704989?lang=en_us&edition=fundamental","pubTime":"2025-03-19 01:05","pubTimestamp":1742317535,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates through a period of volatility, with major indices like the Dow Jones and Nasdaq experiencing fluctuations amid economic uncertainties, investors are increasingly looking for stable opportunities in an unpredictable environment. In such times, companies with high insider ownership can offer a unique appeal, as they often signal strong confidence from those who know the business best and may align their interests closely with shareholders.Top 10 Growth Companies With High Insider Ownership In The United States. Click here to see the full list of 209 stocks from our Fast Growing US Companies With High Insider Ownership screener.Navigate through the intricacies of Pagaya Technologies with our comprehensive analyst estimates report here.Overview: Oddity Tech Ltd. is a consumer tech company that creates digital-first brands for the beauty and wellness sectors globally, with a market cap of approximately $2.56 billion.Oddity Tech demonstrates strong growth ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-high-growth-companies-strong-170535976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","PGYWW","BK4577","BK4085","BK4566","BILI","BK4113","BK4563","ODD","BK4513","BK4554","BK4548","BK4504","BK4503","TBBB","BK4585","BK4510","PGY","BK4588","BK4077","BK4196","BK4531","BK4526","BK4509"],"gpt_icon":1},{"id":"2520096935","title":"BioArctic receives Orphan Drug Designation for exidavnemab the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2520096935","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520096935?lang=en_us&edition=fundamental","pubTime":"2025-03-18 01:54","pubTimestamp":1742234040,"startTime":"0","endTime":"0","summary":"STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB   announced today that the US FDA Office of Orphan Products Development  hasgranted orphan drug designation  to exidavnemab for the treatment of Multiple System Atrophy , providing incentives for the development of treatments for rare diseases with a high medical need.Multiple System Atrophy  is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which controls several basic functions, such as breathing, digestion and bladder control. Currently there is no cure and no available treatment to slow its progression.About MSA Multiple System Atrophy  is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is a synucleinopathy, a group of neurodegenerative dise","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bioarctic-receives-orphan-drug-designation-175400532.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioarctic-receives-orphan-drug-designation-175400532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSA","BIOA","LU1923622291.USD","LU0728928796.USD","LU2125909916.SGD","BK4183","LU2125909759.SGD","LU0053671581.USD","BRCTF","BK4007","LU0757428866.USD","LU2211815571.USD","LU1815336091.USD","BK4143","ODD"],"gpt_icon":0},{"id":"2520542551","title":"Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520542551","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520542551?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:00","pubTimestamp":1742209200,"startTime":"0","endTime":"0","summary":"Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrm Macroglobulinemia. First-in-class Bruton’s tyrosine kinase  degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs. In collaboration with the national naming authority, United States Adopted Name  Council, Nurix’s lead BTK degrader, NX-5948, was assigned the nonproprietary name “bexobrutideg.” The U.S. and international drug naming convention is designed to select a single name of worldwide acceptability for each active substance that is intended to be marketed as a pharmaceutical. Most notable with bexobrutideg is the designation of a new suffix, “deg,” which references bexobrutideg’s novel degradation mode of action. Targeted protein degraders are characterized by their bifunctional nature, binding to both a target protein and a ligase to drive ubiquitination and catalytic degradation of the target through the proteasome. The ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nurix-announces-u-fda-orphan-110000143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2413666699.HKD","LU1989772923.USD","LU0057025933.USD","BK4086","WM","LU2023250504.SGD","LU2362541273.HKD","LU2362540622.SGD","LU2092937221.SGD","LU0175139822.USD","LU2125910336.SGD","LU0511384066.AUD","LU0069063385.USD","LU2041044095.USD","LU2362541513.USD","LU1939255532.USD","LU2089279066.USD","LU2238339852.HKD","LU2106854487.HKD","LU0472753341.HKD","LU2211814178.USD","BK4120","LU2298064838.USD","LU2023250843.SGD","BK4588","LU2065732104.USD","NX","LU1585245621.USD","LU1892829315.USD","LU0289739343.SGD","LU2229751404.USD","LU0289960550.SGD","LU2125910179.SGD","LU1923621640.USD","ODD","LU0124676726.USD","BK4183","LU0347712357.USD","NRIX","LU1917777945.USD","BK4533","LU1974910355.USD","LU1989772840.SGD","LU1430594728.SGD","LU2463526074.USD","BK4139","BK4585","BK4534","LU1721428933.USD","BK4566"],"gpt_icon":0},{"id":"2519315710","title":"Is Oddity Tech Ltd.'s (NASDAQ:ODD) Latest Stock Performance A Reflection Of Its Financial Health?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519315710","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519315710?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:24","pubTimestamp":1742041492,"startTime":"0","endTime":"0","summary":"Oddity Tech  has had a great run on the share market with its stock up by a significant 12% over the last month. Since the market usually pay for a company’s long-term fundamentals, we decided to study the company’s key performance indicators to see if they could be influencing the market. Particularly, we will be paying attention to Oddity Tech's  ROE today.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits.Return on equity can be calculated by using the formula:. Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Oddity Tech is:. Oddity Tech doesn't pay any regular dividends to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oddity-tech-ltd-nasdaq-odd-122452086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","TQQQ","BK4183","BK4112","IE00BKPKM429.USD","NDAQ","NVIW.SI","IE00B64PRP62.GBP","NQmain","ODD","SQQQ","PSQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585",".IXIC","USAW.SI","QLD","LU2210149790.SGD","TSYW.SI","QID","LU2095319765.USD","USJW.SI","BK4588","MNQmain"],"gpt_icon":1},{"id":"2519389886","title":"Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519389886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519389886?lang=en_us&edition=fundamental","pubTime":"2025-03-14 06:07","pubTimestamp":1741903620,"startTime":"0","endTime":"0","summary":"○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042670/0/en/Cellectis-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CAR","CLLS","ODD","BK4139","RCC","BK4231","BK4230","SITC","BK4183","BK4080","EC","BK4201"],"gpt_icon":0},{"id":"2519695478","title":"Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin","url":"https://stock-news.laohu8.com/highlight/detail?id=2519695478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519695478?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:05","pubTimestamp":1741896300,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin. Recent Collaboration Agreement with Abbott Global Enterprises Limited  in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD. Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin. Cadrenal Therapeutics, Inc. , a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin.Full Year 2024 Key Accomplishments and Recent Highlights. Cadrenal appointed James J. Ferguson, MD, FACC, FAHA, as Chief Medical Officer to lead the late-stage clinical development of tecarfarin and other indications in rare cardiovascular conditions requiring life-long anticoagulation the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU1721429402.USD","LU1721429741.USD","LU1061106388.HKD","LU2112291526.USD","LU2237957902.USD","BK4082","BK4592","BK4581","FORD","IE00BJJMRZ35.SGD","SG9999004303.SGD","IE00BJT1NW94.SGD","BK4183","LU1691799644.USD","ABT","BK4604","LU0266013472.USD","IE0009355771.USD","SG9999002232.USD","LENZ","LU1989763690.USD","CVKD","LU1914381329.SGD","LU1989763427.SGD","LU0234572021.USD","BK4007","IE0002141913.USD","CDMO","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1057294990.SGD","LU2237957811.SGD","TM","BK4504","LU2089984988.USD","LU2133065610.SGD","ODD","BK4533","SG9999002224.SGD","BK4585","03160","BK4139","IE00B4R5TH58.HKD","SGXZ23171101.USD","BK4566","LU0868494617.USD","LU0122379950.USD","BK4588","LU0170899867.USD"],"gpt_icon":0},{"id":"2519729859","title":"Oddity Tech (ODD) Just Overtook the 20-Day Moving Average","url":"https://stock-news.laohu8.com/highlight/detail?id=2519729859","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519729859?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:35","pubTimestamp":1741872902,"startTime":"0","endTime":"0","summary":"Oddity Tech  reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ODD broke through the 20-day moving average, which suggests a short-term bullish trend.The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages.Like other SMAs, if a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.Shares of ODD have been moving higher over the past four weeks, up 12.4%. Plus, the company is currently a Zacks Rank #3  stock, suggesting that ODD could be poised for a continued surge.Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. This article originally published on Zacks Investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oddity-tech-odd-just-overtook-133502089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","ODD"],"gpt_icon":0},{"id":"2517457530","title":"Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2517457530","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517457530?lang=en_us&edition=fundamental","pubTime":"2025-03-08 02:49","pubTimestamp":1741373357,"startTime":"0","endTime":"0","summary":"The stock market pulled back to the red territory on Thursday, with all major indices posting significant losses as tariff threats continued to rattle investors.The tech-heavy Nasdaq posted the largest loss, down 2.61 percent, followed by the S&P 500 with 1.78 percent, and the Dow Jones with 0.99 percent.On Thursday, 10 micro and small-cap companies defied a broader market decline, with their share prices jumping by as much as double digits. One company stood out, soaring more than 300 percent during the session.Plus Therapeutics, Inc.  soared by 311.43 percent on Thursday to finish at $1.44 apiece as investors gobbled up shares in the company following the Food and Drug Administration ’s grant of Orphan Drug Designation  to Rhenium Obisbemeda for the treatment of leptomeningeal metastases  in patients with lung cancer.According to Plus Therapeutics, Inc. , ODD provides certain benefits to drug developers, including seven potential years of market exclusivity, tax credits for qualified","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-plus-therapeutics-inc-pstv-184917916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","TSYW.SI","BK4183","QLD","ODD","MNQmain","PSTV","TQQQ","QID","BK4139","USAW.SI","PSQ","SQQQ",".IXIC","NVIW.SI","USJW.SI"],"gpt_icon":1},{"id":"2517843003","title":"Oddity Tech Ltd. (ODD): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2517843003","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517843003?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:04","pubTimestamp":1741363440,"startTime":"0","endTime":"0","summary":"We came across abullish thesison Oddity Tech Ltd.  on Substack by Lorenzo Bastianelli. In this article, we will summarize the bulls’ thesis on ODD. Oddity Tech Ltd. 's share was trading at $44.05 as of March 6th. ODD’s trailing P/E was 26.84 according to Yahoo Finance.Despite the strong financial performance, one concerning metric is organic website traffic, which has been flat to declining YoY for both IL MAKIAGE and SpoiledChild. This suggests that while the company is excelling at engaging existing customers—evidenced by higher order values and strong retention—it is not significantly expanding its new customer base through word-of-mouth at the expected pace. This divergence between revenue growth and organic traffic warrants further scrutiny, as sustained growth will require continued customer acquisition alongside increased spending from loyal customers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oddity-tech-ltd-odd-bull-160400041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAGR","BK4159","ODD","BK4183"],"gpt_icon":0},{"id":"2517694151","title":"Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694151","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517694151?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"HOUSTON, March  06, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","LENZ","CSF","BK4183","ODD","BK4202","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":164,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-29","symbol":"ODD","fiscalQuarterEnding":"2025/03","expectedEps":0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"post","actualEps":0.63},{"market":"US","date":"2025-02-25","symbol":"ODD","fiscalQuarterEnding":"2024/12","expectedEps":0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"post","actualEps":0.06},{"market":"US","date":"2024-11-06","symbol":"ODD","fiscalQuarterEnding":"2024/09","expectedEps":0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":0.29},{"market":"US","date":"2024-08-07","symbol":"ODD","fiscalQuarterEnding":"2024/06","expectedEps":0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":0.71},{"market":"US","date":"2024-05-07","symbol":"ODD","fiscalQuarterEnding":"2024/03","expectedEps":0.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715054400000,"reportTimeType":"post","actualEps":0.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.5556,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1738382400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2025-06-13","current":38.84497,"percent":0.738758,"low":20.831575,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"high":144.174884,"avg":34.927998,"sd":17.317062,"marketCap":4130735251},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251}],"updateTime":1749894749713}}}